Aptose Biosciences Inc (APTO)

[dcaf7]

A few notes from today's RBC presentation.
1. In a couple of weeks, we do have a meeting established. Have a couple of goals for that, one is to establish a RP2D, another is ancillary studies, need healthy volunteer studies, food, fasted, that you can combine drugs, you have to do 13-weeks chronic tox studies, those are ongoing (is it in rats?). And also, to get an idea of registrational path we want to do and some agreements on the terms, what is response rate needed in different categories, r/r, 2nd, 1st line.
2. More data with doublet in October at ESH meeting.
3. Commercial opportunity for Flt3i failures, patients with TP53 mut, Ras mut, each is about $15M (or $50M? not clear).
4. Lux. We don't have money we need to support Lux studies but it is still in clinic. We expect to enroll back, especially patients with B-cell malignancies, DLBCL, MCL, FL, also move into inflammation models.
https://www.veracast.com/webcasts/rbc/healthcare2023/T5xwmm.cfm